entity

TAU_1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAU_1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections

20Hypotheses

0Analyses

1Outgoing

2Incoming

0Experiments

0Debates

No AI portrait yet

Outgoing (1)

Target	Relation	Type	Str
AD_2	associated_with	disease	0.72

Incoming (2)

Source	Relation	Type	Str
HNRNPA2B1_1	regulates	gene	0.64
MEPCE_1	regulates	gene	0.64

Targeting Hypotheses (20)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Temporal Decoupling of CSF p-tau217 Normalization from Amylo	0.595	neurodegeneration	-
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho	0.586	neurodegeneration	-
Residual Vascular Amyloid Prevents Complete CSF p-tau217 Nor	0.585	-	Can CSF p-tau217 normalization serve as
CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET N	0.565	-	Can CSF p-tau217 normalization serve as
Gamma-Entrained PV Interneuron Networks Enable Precision p-t	0.550	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp

Gamma-Entrained PV Interneurons Enable p-tau217-Guided Preci	0.547	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Combined p-tau217 + p-tau231 Panel Increases Specificity for	0.546	neurodegeneration	-
Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extrac	0.542	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Microglial Reactivation Status Modifies Amyloid Clearance an	0.524	neurodegeneration	-
CSF p-tau217 Normalization Requires Intact Synaptic Function	0.515	neurodegeneration	-
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clini	0.512	neurodegeneration	-
Neurogranulin Predicts p-tau217 Reliability by Identifying P	0.498	neurodegeneration	-
Amyloid Plaque Clearance Triggers Downstream Reduction in Ta	0.475	-	Can CSF p-tau217 normalization serve as
Gamma-Entrained PV Interneurons Enable Precision p-tau217-Gu	0.464	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-	0.431	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Neurogranin Co-Normalization Validates p-tau217 as a Surroga	0.415	-	Can CSF p-tau217 normalization serve as
Axonal Integrity Recovery Following Amyloid Clearance Drives	0.365	-	Can CSF p-tau217 normalization serve as
Individual Baseline Variability in p-tau217 Half-Life Dictat	0.335	-	Can CSF p-tau217 normalization serve as
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00	0.323	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
P-tau217 Isoform Shift Indicates Mechanistic Transition Poin	0.245	-	Can CSF p-tau217 normalization serve as

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning TAU_1 in their description or question text

Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRN

Score: 0.547 · molecular-neurobiology · 2026-04-17

## Mechanistic Overview Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRNA Therapeutics i

Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Deli

Score: 0.542 · molecular-neurobiology · 2026-04-17

## Mechanistic Overview Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0

Amyloid Plaque Clearance Triggers Downstream Reduction in Tau Kinase Activity, N

Score: 0.475 · unknown disease · 2026-04-26

Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, which diminishes the path

Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome

Score: 0.464 · molecular-neurobiology · 2026-04-21

## Mechanistic Overview Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome Therapy in Early

Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy

Score: 0.431 · molecular-neurobiology · 2026-04-21

## Mechanistic Overview Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy Precision in Ea

Neurogranin Co-Normalization Validates p-tau217 as a Surrogate for Synaptic Heal

Score: 0.415 · unknown disease · 2026-04-26

CSF p-tau217 normalization must co-occur with neurogranin (Ng) stabilization to confirm cessation thresholds. Ng reflect

Axonal Integrity Recovery Following Amyloid Clearance Drives CSF p-tau217 Normal

Score: 0.365 · unknown disease · 2026-04-26

Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment. Restored axo

Individual Baseline Variability in p-tau217 Half-Life Dictates Cessation Thresho

Score: 0.335 · unknown disease · 2026-04-26

CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter

Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Windo

Score: 0.323 · molecular-neurobiology · 2026-04-17

## Mechanistic Overview Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD starts f

P-tau217 Isoform Shift Indicates Mechanistic Transition Point for Cessation Elig

Score: 0.245 · unknown disease · 2026-04-26

Donanemab treatment causes a shift from disease-specific p-tau217 (produced via amyloid-driven kinase activation) toward